Protein-based drugs are big business, worth more than $17 billion a year. Genetically engineered bacteria and yeast efficiently churn out many protein pharmaceuticals, but as the proteins get more complex, the simple microbes sometimes fail. Drugmakers must then turn to increasingly expensive systems to make the proteins, which drives prices through the roof. Pittsboro, NC-based Biolex may have found an alternative: genetically engineer duckweed, a flowering pond plant, to secrete human proteins. The tiny plants grow very rapidly in a simple nutrient solution-doubling in population every 36 hours-and contain exceptionally large amounts of proteins. Biolex has proved the plants can do the work by using them to make complex therapeutic proteins such as interferons, which are used to treat some forms of cancer and hepatitis. The company is tweaking the system to increase efficiency and says that duckweed-produced drugs could be ready for testing in two to four years.
This new data poisoning tool lets artists fight back against generative AI
The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models.
The Biggest Questions: What is death?
New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.
Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist
An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.
How to fix the internet
If we want online discourse to improve, we need to move beyond the big platforms.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.